Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Baroni

Makes perfect sense, since a merger with TPL is mentioned in RG's contract.

100% of the shares subject to the Event Bonus Option will vest, and Executive's interim position will be converted to standing President/CEO, upon the effective date of any one of the following events: (i) the successful closing of a merger or acquisition brought forth primarily due to the efforts of Executive (excluding any merger or acquisition with TPL or any affiliated company) as approved by the Board of Directors

http://msnmoney.brand.edgar-online.com/DisplayFilingInfo.aspx?TabIndex=2&FilingID=5950057&companyid=6305&ppu=%252fDefault.aspx%253fticker%253dptsc

.

.

Be well

Share
New Message
Please login to post a reply